The score is primarily constrained by very weak financial performance (deep losses, cash burn, and a stressed balance sheet with negative equity). Technicals are only neutral and do not offset the fundamental risk, while valuation remains pressured due to negative earnings and no indicated dividend yield support.
Positive Factors
Proprietary aluminum foam product niche
Cymat’s core offering is proprietary aluminum foam used for impact mitigation, vibration damping and lightweight structural performance. That specialized materials position creates durable technical differentiation, supports OEM supply relationships, and targets structural end-markets with recurring needs.
Lean operating footprint
A very small headcount implies a lean cost structure and operational flexibility. For a manufacturing-technology business this can extend runway, reduce fixed overhead, and allow management to prioritize capital spending or contract manufacturing to scale with orders without large permanent payroll commitments.
Historical positive gross margin (~13.3% in 2025) indicates the product can be profitably manufactured under better operating conditions. This implies that if revenue or cost structure normalizes, the business model retains the potential for margin recovery and improved unit economics over the medium term.
Negative Factors
Stressed balance sheet with negative equity
Negative equity and meaningful debt on a small asset base materially limit financial flexibility. This structural capital weakness increases refinancing and solvency risk, constrains ability to fund operations or invest, and makes the company sensitive to even modest cash-flow disruptions over months.
Persistent operating cash burn and negative FCF
Sustained negative operating and free cash flow indicate the business is consuming cash to fund ongoing operations. Over the medium term this necessitates external financing or asset sales; given the weak balance sheet, continued cash burn heightens liquidity and survival risk and limits investment in growth or stabilization.
Declining revenue and deeply negative profitability
Revenue decline with a negative gross margin and extreme net losses signal structural demand, pricing, or cost issues. Negative unit economics undermine scalability and mean the firm must improve pricing, reduce costs, or gain scale quickly to restore sustainable profitability over the coming months.
Cymat Technologies (CYM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.53M
Dividend YieldN/A
Average Volume (3M)118.58K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-25.74%
EPS Growth2.28%
CountryCA
Employees11
SectorGeneral
Sector StrengthN/A
IndustryManufacturing - Metal Fabrication
Share Statistics
EPS (TTM)-0.01
Shares Outstanding100,337,330
10 Day Avg. Volume20,030
30 Day Avg. Volume118,582
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-2.03
Price to Sales (P/S)2.58
P/FCF Ratio-5.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cymat Technologies Business Overview & Revenue Model
Company DescriptionCymat Technologies Ltd., a materials technology company, manufactures and sells stabilized aluminum foam products worldwide. The company provides architectural materials under the Alusion brand name; and automotive and blast mitigation products under the SmartMetal brand name. It serves defense and military, automotive and transportation, architectural, and other application. The company was incorporated in 2006 and is based in Mississauga, Canada.
How the Company Makes MoneyCymat Technologies generates revenue primarily through the sale of its Alusion® stabilized aluminum foam products to various industries, including construction, automotive, aerospace, and defense. The company capitalizes on its proprietary technology by licensing its manufacturing processes to partners, which provides a secondary revenue stream. Additionally, Cymat engages in strategic partnerships with companies within these sectors to enhance its market reach and product development, enabling it to secure contracts and expand its customer base. The company's earnings are also bolstered by ongoing research and development initiatives that aim to innovate and improve its product offerings, allowing it to meet the evolving needs of its clients.
Cymat Technologies Financial Statement Overview
Summary
Financials indicate severe strain: TTM revenue declined (-4.2%), gross margin turned negative (~-2.4%), losses are extremely large versus sales (net margin ~-222%), and both operating cash flow and free cash flow are materially negative (~-$2.75M and ~-$2.77M). The balance sheet is also stressed with negative equity (~-$3.8M) and meaningful debt (~$5.8M) on a small asset base, limiting flexibility and increasing refinancing/liquidity risk.
Income Statement
12
Very Negative
TTM (Trailing-Twelve-Months) results show deep and worsening profitability pressure: revenue declined (-4.2% growth) and gross profit turned slightly negative (gross margin ~-2.4%). Losses remain very large versus sales (net margin ~-222%), with negative EBIT and EBITDA margins as well. While the prior annual period (2025) had positive gross margin (~13.3%), the business is still structurally unprofitable with persistent net losses across the history provided.
Balance Sheet
9
Very Negative
The balance sheet is highly stressed with negative shareholders’ equity in TTM (about -$3.8M) and elevated debt (~$5.8M) relative to a small asset base (~$3.7M). Negative equity makes leverage risk materially higher and limits financial flexibility. Debt has also increased versus the most recent annual period (2025), reinforcing refinancing and liquidity sensitivity if operating performance does not improve.
Cash Flow
14
Very Negative
Cash generation is weak: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both meaningfully negative (about -$2.75M and -$2.77M, respectively), implying continued cash burn. A positive free cash flow growth figure is a modest improvement signal, but it is from a negative base and does not change that the company is funding ongoing losses and operations with external capital or balance-sheet resources.
Breakdown
TTM
Jul 2025
Jul 2024
Jul 2023
Jul 2021
Jul 2020
Income Statement
Total Revenue
1.83M
3.71M
1.62M
3.05M
4.15M
1.69M
Gross Profit
-43.88K
494.39K
-412.85K
-270.42K
2.12M
373.27K
EBITDA
-2.48M
-1.91M
-3.34M
-5.45M
252.17K
-1.51M
Net Income
-4.06M
-3.37M
-4.27M
-6.05M
-543.00K
-1.81M
Balance Sheet
Total Assets
3.68M
2.76M
3.96M
4.16M
6.58M
1.86M
Cash, Cash Equivalents and Short-Term Investments
926.84K
354.03K
56.27K
324.05K
5.02M
251.58K
Total Debt
5.81M
5.58M
2.94M
2.28M
1.38M
1.06M
Total Liabilities
7.50M
7.49M
6.78M
4.77M
3.71M
2.75M
Stockholders Equity
-3.83M
-4.73M
-2.81M
-612.07K
2.88M
-889.52K
Cash Flow
Free Cash Flow
-2.77M
-1.64M
-2.26M
-3.49M
401.48K
-1.38M
Operating Cash Flow
-2.75M
-1.60M
-2.23M
-2.46M
432.92K
-1.33M
Investing Cash Flow
-20.13K
-37.52K
-31.32K
-1.03M
-31.44K
-47.92K
Financing Cash Flow
3.46M
1.93M
1.99M
1.18M
4.36M
1.45M
Cymat Technologies Technical Analysis
Technical Analysis Sentiment
Negative
Last Price0.12
Price Trends
50DMA
0.11
Negative
100DMA
0.11
Negative
200DMA
0.13
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
33.12
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CYM, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.11, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.12 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CYM.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026